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Yeast-based drug screening assayCross-complementation studies offer the possibility to overcome limitations imposed by the inherent complexity
of multicellular organisms in the study of human diseases, by taking advantage of simpler model organisms like
the budding yeast Saccharomyces cerevisiae. This review deals with, (1) the use of S. cerevisiae as a model organ-
ism to study human diseases, (2) yeast-based screening systems for the detection of disease modiﬁers, (3)
Hailey–Hailey as an example of a calcium-related disease, and (4) the presentation of a yeast-based model to
search for chemical modiﬁers of Hailey–Hailey disease. The preliminary experimental data presented and
discussed here show that it is possible to use yeast as a model system for Hailey–Hailey disease and suggest
that in all likelihood, yeast has the potential to reveal candidate drugs for the treatment of this disorder. This ar-
ticle is part of a Special Issue entitled: Calcium signaling in health and disease. Guest Editors: Geert Bultynck,
Jacques Haiech, Claus W. Heizmann, Joachim Krebs, and Marc Moreau.
© 2014 Elsevier B.V. All rights reserved.1. Yeast as a model system for human diseases
Budding yeast Saccharomyces cerevisiae is a prototype of eukaryotic
cell with a complete set of basic eukaryotic genes. It is experimentally
tractable with a rapid doubling time and very simple culture conditions;
yeast is thus a eukaryote as easy to handle as a prokaryote. In addition,
a tremendous number of powerful tools are available when working
with this simple unicellularmodel. These tools range fromclassical genet-
ics to cell biology, biochemistry and molecular genetics. Indeed, budding
yeast genome was the ﬁrst eukaryotic genome to be sequenced (the
whole sequence was released in April 1996 [1]) and can be modiﬁed at
will at the nucleotide level. Therefore, all its essential genes have been
identiﬁed. They roughly represent one third of its≈6200 genes. Subse-
quently, libraries of yeast strains deleted (haploid or diploid strains het-
erozygous for these deletions) for every single gene were developed.
Libraries of yeast strains over-expressing every single genewere also cre-
ated. All these collections are easily accessible and molecular barcoded
thus allowing a number of automated chemogenomic approaches aiming
at deciphering the cellular pathways targeted by a given compound ([2]
and see below). In addition, a huge number of systematic approachesSignaling in Health and Disease.
Heizmann, Joachim Krebs, and
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el).(transcriptomic, proteomic, locabolomic, interactomic, metabolomic,
etc.) have been carried out in yeast and their results are freely available.
Thanks to the richness of this molecular toolbox, yeast has long been
used as a powerful model system for basic research on the most funda-
mental cellular mechanisms. This was true in a number of different
ﬁelds including, among many others, study of mitochondrial functions
(incidentally, the mitochondrial genome was ﬁrst discovered in yeast
[3]), transcription, translation, DNA replication or secretion. One of the
most spectacular examples stands in the cell cycle ﬁeld where budding
yeast S. cerevisiae and ﬁssion yeast Schizosaccharomyces pombewere in-
strumental for elucidating the most fundamental and conserved cell
cycle regulatory mechanisms like CDK/cyclin, the master regulator of
the eukaryotic cell cycle. The discovery of the budding and ﬁssion
yeast CDK/cyclin complexes led to the attribution of the Nobel Prize in
Medicine and Physiology in 2001 to Lee Hartwell and Paul Nurse, re-
spectively [4,5]. Of note, CDK/cyclin complexes were subsequently
widely used as therapeutic targets to identify new drugs for the treat-
ment of cancers [6,7]. The most recent illustration of the power of the
yeast model is given by the attribution of the 2013 Nobel Prize in Med-
icine and Physiology to Randy Schekman for his seminal discovery of
machineries regulating vesicular trafﬁcking using a brilliantly conceived
genetic screen that allowed isolation of the secmutants that accumulate
secretory pathway intermediates.
Following this long-lasting use as a powerful model system, the ver-
satile genetic ﬂexibility of yeast and the high degree of conservation be-
tween yeast andmammalian cellular processes have alsomade yeast, in
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yeast S. pombe), an invaluable tool for modeling human diseases. These
yeast models enable identiﬁcation and characterization of key actors
and cellular pathways involved in the considered disorders, and thereby
new therapeutic targets that can later on be used for various subsequent
pharmacological screenings which can themselves be based on yeast.
Indeed, not only most of the basic cellular functions are conserved
from yeast to humans, but also the diseases' key players themselves
are often conserved: it is indeed estimated that at least 30% of the
genes associated with human diseases have functional homologs in
the S. cerevisiae genome [8]. For all these reasons, yeast has been in-
creasingly used as a model and tool for biomedical research over the
past one or two decades [9,10].
2. Use of yeast models for diagnostics, therapeutic molecule
production and drug screening
The use of yeast now extends from the ﬁeld of diagnostics to drug
production and discovery. For example, an elegant yet simple yeast-
based assay, the so-called FASAY (Functional Analysis of Separated Al-
leles in Yeast) assay, has been developed for assessing the functionality
of the tumor suppressor gene p53 [11,12], a crucial piece of information
with respect to the choice of treatment for many cancers. Yeast can also
be used as a factory to produce therapeutic compounds such as hydro-
cortisone [13], a major steroid for the pharmaceutical industry which
hemi-synthesis from naturally occurring sterols was involving a com-
plex and sophisticated multi-step chemical procedure and a microbial
bioconversion step [13], or amorphadiene, a precursor of artemisin, an
antimalarial drug [14]. In addition, yeast is increasingly used for creating
simple cellular models of human diseases for many different applica-
tions, in particular for various systematic approaches such as drug and
genetic screenings (Fig. 1). This is particularly true in the ﬁeld of
human inherited disorders. In order to create a proper yeast model for
a given human pathology, it is ﬁrst necessary to get a phenotype
which is relevant, i.e. close to the known pathological mechanism and
easy to follow using classical yeast tools. In the simplest andmost direct
cases, like human inherited diseases where a functional homolog of the
affected protein in human exists in yeast, the mutated forms of theFig. 1. Creation and use of yeasthuman culprit proteins can be expressed directly in yeast strains in
which the corresponding yeast genes have been deleted. Hence, the
use of yeast to determine the functionality of mutated alleles of genes
involved in genetic diseases has been largely exploited in theﬁeld ofmi-
tochondrial diseases (for review see [15]). Alternatively, the identiﬁed
mutations in the human genes can be introduced at synonymous posi-
tions in the corresponding yeast genes (Fig. 1A). This type of approach
has been used for the NARP (Neuropathy, Ataxia, Retinitis Pigmentosa)
syndrome, a devastating mitochondrial disease which is due to point
mutations in themitochondrially-encoded ATP6 gene [16]. Since a strict
parallel between the severity of the mutations in patients and in yeast
was observed, the yeast NARP models were used to identify genes and
drugs that suppress their respiratory growth phenotype [16,17]. These
yeast-NARP models were further validated when these drugs were
shown to also suppress the respiratory growth of cells derived from
NARP patients. This particular example highlights two other strengths
of S. cerevisiae: (i) its ability to survive either by fermentation or by res-
piration (only the latter requires oxidative phosphorylation) and (ii) the
fact that togetherwith Chlamydomonas reinhardtii [18], budding yeast is
the only eukaryote inwhich site-directedmutagenesis of themitochon-
drial genome has been established, based on biolistic techniques [19], in
addition to site-directed mutagenesis of the nuclear genomewhich has
long been established.
When functional orthologs of human genes exist, in addition to being
used as a test tube for determining the functionality of mutated alleles
of genes involved in genetic diseases, yeast can also be used to identify
the so-called modiﬁer genes in yeast-based “phenomic” models. This
approach has been successfully used for deciphering potential modiﬁer
genes of CFTR-ΔF508, by far the most prevalent allele of the CFTR gene
responsible for cystic ﬁbrosis [20,21].
In the absence of a functional ortholog, yeast models can still be cre-
ated by using yeast genes as prototypes, as it has been performed for
prion-related diseases (Fig. 1B and [22]). Indeed, although they present
no homology with the mammalian prion PrP, yeast prions themselves
were used as models for PrP, based on the initial assumption that
prion-controllingmechanismsmay be conserved throughout evolution.
Of note, like their mammalian counterpart, yeast prions form autocata-
lytic amyloid ﬁbers which are partially resistant to proteinase K. A yeastmodels for human diseases.
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their activity against two unrelated yeast prions [22–24]. The isolated
active molecules then turned out to be active against mammalian
prion both in cell-based assays and in vivo in a mouse model for prion
diseases, thereby not only validating the yeast-based drug screening
assay but also S. cerevisiae for studying prion biology [25,26]. Important-
ly, this study constitutes the ﬁrst functional evidence that at least some
cellular mechanisms involved in prion propagation are conserved from
yeast to human. For this reason, the active drugs isolated were used in
reverse chemical biology studies [27] that highlight the protein folding
activity of the ribosome (PFAR) as a new putative player and therefore
therapeutic target for prion diseases [27–29].
More complex are the situations where neither functional ortholog
nor prototype gene exists in yeast. In these cases, humandiseasemodels
can be created by heterologous expression of the human culprit protein
in yeast (Fig. 1C). This type of approachhas been largely used in theﬁeld
of neurodegenerative diseases like Huntington disease [30,31] or
Parkinson disease [32]. Although the human proteins involved in
these diseases have no functional homolog in yeast, upon expression
in this organism they form amyloid ﬁbers that can even, at least in
some cases and/or situations, be toxic for yeast cells, therebymimicking
the situation observed in human neuronal cells. A nice example of this
approach was given by the creation of a yeast model for Huntington
disease [30], a familial fatal neurodegenerative disorder caused by the
expansion of a polyglutamine tract in the Huntingtin protein (Htt).
A mutant form of the ﬁrst exon of Htt containing the expanded
polyglutamine domain (103Q instead of 25Q in the wild type allele)
was expressed in budding yeast. Htt103Q aggregated and was toxic to
yeast cell as in patients' neuronal cells. In contrast, the wild type ﬁrst
exon of Huntingtin (Htt25Q) did not aggregate and was not toxic in
yeast cells. The authors then used a collection of haploid strains deleted
for every single non-essential yeast genes and found that aggregates of
Htt103Q were not toxic in some yeast mutants, including the mutant
strain in which the BNA4 gene was deleted. This discovery suggested
that this gene, which encodes kynurenine 3-monooxygenase (KMO),
an enzyme of the kynurenine pathway of tryptophan degradation high-
ly conserved from yeast to humans, is a putative therapeutic target for
the treatment of Huntington disease. This hypothesis was later on phar-
macologically validated using chemical inhibitors of KMO in animal
models for both Huntington and Alzheimer diseases [33].
Therefore, in all of these models, the basic idea is always the same:
obtaining a yeast phenotype that is relevant for the considered disor-
ders which then offers the possibility to search for modiﬁers that either
suppress or exacerbate such given phenotype. Modiﬁers can include
drugs, genes or any other biological or chemical moiety. In addition, for-
ward chemical genetics approaches can be performed in yeast for the
discovery of chemical probe targets [2].
3. Yeast models for calcium-related diseases
Diverse Ca2+ signals regulate fundamental functions in neuronal biol-
ogy, including synaptic transmission and plasticity, neurite outgrowth or
synaptogenesis, and play an essential role in cell proliferation and differ-
entiation,DNA transcription and apoptosis. For instance, themitochondri-
al cell death pathway is triggered by elevated Ca2+ concentrations [34].
S. cerevisiae has been widely used to study Ca2+ transporters, as well as
Ca2+ homeostasis and signaling. These studies have shown that the
essential components of the cellular Ca2+ signaling machinery are con-
served from yeast to human, including Ca2+ channels and transporters,
Ca2+ sensors and signal transducers [35]. Despite its omnipresence,
Ca2+ displays very distinct and extremely speciﬁc role in each part of
the cell [36]. Cells exclude Ca2+ from their interior (vertebrates maintain
a low basal (Ca2+)i of 50–100 nM) to avoid dangerous consequences of
Ca2+ and to use its binding energy for signal transduction in a controlled
manner [37]. To control cytosolic Ca2+ concentrations, cells have com-
partmentalized the storage of Ca2+ in organelles such as the endoplasmicreticulum, mitochondria, nucleus and the Golgi apparatus [38,39]. Mito-
chondrial Ca2+ uptake by a mitochondrial calcium uniporter activity is
evolutionarily conserved in vertebrates and in kinetoplastids [40,41] yet
not measurable in S. cerevisiae [42–44]. Moreover, the role of Ca2+ ions
stored in the mitochondria and endoplasmic reticulum is well under-
stood, whereas the importance of the Golgi apparatus as a Ca2+ store is
less studied [45,46]. Controlled release of Ca2+ from these organelles
and theway inwhich it travels in the cell (as sparks, waves, etc.) transmit
signals fromone part of the cell to another. This is accomplished by sever-
al calcium binding proteins (CaBPs) [47]. Classic examples of such pro-
teins are parvalbumin and calmodulin [48]. Calcium sequestered in the
Golgi apparatus lumen is mainly buffered by CALNUC (nucleobindin)
[49], Cab45 [50] and P54/NEFA [51], and while the function of CALNUC
is well characterized in human cells, little is known about orthologous
genes in other organisms including yeast [52].
A major difference is that, as most of the time observed, yeast is a
simpliﬁedmodel of eukaryotic cell so that it lacks redundancy of multi-
ple isoforms and the complexity of splice variants that are characteristic
ofmammalian cells. Instead, there is a limited number of genes thatmay
be deleted individually or in combination to decipher their exact role in
Ca2+ homeostasis and signaling. An example is provided by a recent
study which shows that overexpression of the main Parkinson disease
mediator α-Synuclein (αSyn) drives changes in Ca2+ homeostasis and
confers cytotoxicity in yeast, nematodes and ﬂies [53]. Such cytotoxicity
can be explained by an increase in cytosolic Ca2+ that precedes a burst
of oxidative radicals that ultimately triggers cell death. Consequently,
the cytocidal effects of αSyn can be reduced by treatment of cells with
Ca2+ chelators or with the generic antioxidant N-acetylcysteine (NAC).
Hailey–Hailey disease (HHD), or benign familial pemphigus, is an
autosomal dominant blistering skin disorder that is triggered by friction,
heat, sweating, stress, infection, or ultraviolet radiations [54], and man-
ifests in the 3rd or 4th decade of life [55]. Histologically, HDD is charac-
terized by disruption of cell-to-cell adhesion (acantholysis) in the
suprabasal layer of the epidermis [56,57]. Of note, HDD patients might
have an increased incidence of cancer. Indeed, HHD-dependent skin le-
sions may develop into squamous cell carcinomas [58,59] as well as
melanomas [60]. The molecular causes of HHD are mutations in the
ATP2C1 gene [61,62]. ATP2C1 encodes the secretory pathway Ca2+/
Mn2+ ATPase SPCA1 (secretory pathway Ca2+ ATPase) which actively
transports Ca2+ and Mn2+ from the cytosol to the lumen of the Golgi
[54]. Several studies relate the decline in SPCA1 levels to alterations in
the regulation of apoptotic processes and to an increase in reactive ox-
ygen species (ROS) in mice [63,64] and primary human keratinocytes
derived from HHD patient skin [65]. ATP2C1 is an essential gene in
mice and null mutant Spca1−/− embryos did not survive beyond gesta-
tion day 10.5 [64]. Interestingly, in line with the development of squa-
mous cell carcinomas and the increased incidence of cancers in HDD
patients, heterozygous mutation of the ATP2C1 gene leads to an in-
creased incidence of squamous cell tumors in aged mice [64]. However,
ATP2C1+/−mice show no evidence of HHD, whichmay be related to the
late onset of HHD symptoms, but rather corroborate the need for
additional genetic or non-genetic factors for the clinical manifestation
of HHD. The difﬁculty to generate a relevant mammalian HHD model
can be partially overcome by the analysis of HHD patient-derived or
SPCA1 depleted keratinocytes. Keratinocytes lacking SPCA1 display an
increase of the tight junction forming proteins Claudins 1 and 4 [66],
while ROS have been shown to provoke a miRNA mediated down-
regulation of Notch1, p21CWaf1/Cip1, and Itch, and a differential ex-
pression of p63 isoforms in keratinocytes from HHD patients [67]. Of
note, Notch1 and p63 are part of a regulatory signaling network which
function is essential for the control of keratinocyte proliferation, differ-
entiation and cell adhesion [68,69].
To date, there is no cure for HHD and the treatment of HHD patients
only aims at reducing symptoms or preventing disease-triggering fac-
tors such as exposure to sunlight, friction or skin sweating. An example
for the latter is the use of Botulinum toxin to reduce sweating and
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fungal, antibiotic or antiviral treatments to control secondary infections
[71–73], and corticosteroids to reduce inﬂammation [71,74]. In some
cases, skin transplantation or vaporization of the affected skin by a
carbon-dioxide laser has been successfully applied [75–77]. Reports on
HHD treatments aremainly based on case studies. These reports include
photodynamic treatment [78] or the topical application of active com-
pounds. Aminoglycosides have been found to be potential pharmacoge-
netic agents in HHD treatment [79]. Aminoglycosides are known to
increase the frequency of stop codon readthrough [80], thus this treat-
mentmay be limited to patients carrying a premature stop codon with-
in the ATP2C1 gene. Another successful approach for HHD treatment
takes advantage of topical vitamin D3 derivatives, such as calcitriol or
tacalcitol [81–84]. A case study for such treatment is shown in Fig. 2A
[83]. It is interesting to note that these compounds can induce the differ-
entiation of epidermal keratinocytes into squamous and denucleated
horny cells by regulating inter- and intra-cellular Ca2+ concentrations
[85,86].
Both the yeast S. cerevisiae and Kluyveromyces lactis (K. lactis) PMR1
(plasmamembrane ATPase related) genes encode a functional homolog
of ATP2C1, as its function in concentrating Ca2+ and Mn2+ in the Golgi
can be fulﬁlled by ATP2C1 [35]. Thus, it is possible to use S. cerevisiae or
K. lactis PMR1 genes to study some aspects of ATP2C1 function [87,88],
in particular to determine the functionality of mutated alleles of ATP2C1
found in patients. Although Pmr1p is not essential in both yeast species,
cells deprived of Pmr1p display pleiotropic phenotypes, some of them
resembling those reported in HHD keratinocytes [61,62], includingFig. 2. Examples for calcium-related suppression of HHD and pmr1Δ phenotypes.
(A) Clinical photograph of a HHD patient before (left) and after one month topical
tacalcitol treatment (right). Taken from [58]. Extracellular calcium can suppress several
pmr1Δ-dependent phenotypes such as (B) underglycosylation of CPY (p1= unglycosylated,
p2 = glycosylated, m = mature CPY) and (C) sensitivity to the ﬂuorescence brightener
calcoﬂuor white (CFW).alterations in Ca2+ homeostasis, mitochondrial fate and ROS accumula-
tion [53,87,89].
The pmr1Δ mutant fails to clear Ca2+ and Mn2+ from the cytosol,
thus being sensitive to elevated extracellular levels of these ions
[90,91]. This mutant is also sensitive to depletion of extracellular Ca2+
or Mn2+ by chelating agents such as BAPTA or EGTA [92,93]. As a result
of Ca2+ and Mn2+ deﬁciency within the ER and Golgi, the pmr1Δmu-
tant is defective in protein sorting and processing through the secretory
pathway, and is sensitive to ER stress [94–96]. Golgi-hostedMn2+ is es-
sential for correct N-linked protein glycosylation in the cis-Golgi appa-
ratus and invertase or carboxypeptidase Y (CPY) underglycosylation is
a hallmark of pmr1Δ [94,95].Moreover, alterations in protein processing
cause an accumulation of chitin in the pmr1Δ mutant such that it
becomes hypersensitive to the chitin binding stilbene ﬂuorescent bright-
ener calcoﬂuor white (CFW) [97]. Interestingly, many of the pmr1Δ-
mediated phenotypes are due to an impaired Mn2+ transport [98], and
somephenotypes can be alleviated by growing cells in the presence of ex-
tracellular CaCl2 [94,99,100]. An example is given in Fig. 2 showing that
extracellular CaCl2 can rescue CPY glycosylation defects (Fig. 2B) as well
CFW-sensitivity (Fig. 2C).
4. Yeast-based identiﬁcation of Hailey–Hailey disease modiﬁers
The fact that Hailey–Hailey is a localized skin disease facilitates
treatment of affected body parts by topical treatment. Although extra-
cellular Ca2+ can alleviate numerous pmr1Δ-dependent phenotypes
[94,99–101], it seems that topical CaCl2 is not effective in HHD treat-
ment. However, the successful application of vitamin D3 derivatives
shows that targeted modulation of intracellular Ca2+ levels indeed
counteracts the outcome of ATP2C1 dysfunction in some HHD patients
[81–84]. To extendour knowledge on compounds that improve the con-
dition of HHD patients, we initiated a screen for compounds that – alike
extracellular Ca2+ – overcome a given phenotype of the yeast pmr1Δ
mutant. We reasoned that the identiﬁcation of positive hits would pro-
vide a primary set of compounds that can be further tested on human
cell culture models of Hailey–Hailey disease. For the sake of simplicity,
the initial screening system was based on the CFW-sensitivity of the
pmr1Δmutant (Fig. 3A and see Fig. 1).
The FDA-approved Prestwick (1200 compounds) and TEBU (640
compounds) chemical libraries were screened for suppressors of pmr1
Δ CFW-sensitivity, and allowed isolation of≈30 positive hits, among
which 4 compounds were ﬁnally validated (Fig. 3B). According to
theirmodes of action, these compounds belong to various families rang-
ing fromdopamine antagonists to enzyme inhibitors. However, themo-
lecularmechanisms bywhich these compounds improve cell survival of
pmr1Δ still need to be deciphered. These drugs now need to be validat-
ed on human cell-based models of Hailey–Hailey disease.
5. Conclusions and perspectives
As mentioned in the introduction, the list of functional S. cerevisiae
orthologs of genes associated with human diseases is steadily growing
and the potential to use yeast for the study of human diseases is far
from being fully explored. Apart from the study of common diseases
such as cancers or neurodegenerative diseases, yeast might be especial-
ly useful for the study of rare diseases such as Hailey–Hailey disease for
which research is constrained by the limited number of patients. Appar-
ently, the frequency of HHD in a populationmay be as low as 1 in a mil-
lion (http://haileyhailey.com/). Financial support of patients suffering
from a rare disease is mainly restricted to private donations, although
most of the known 6000–8000 rare diseases are lacking therapies de-
spite many of them being life-threatening or chronically debilitating.
Such restrictions highlight the need for the development of alternative
diseasemodel systems that offer the prospect to rapidly screen for ther-
apeutic molecules in an economically-sound manner.
Fig. 3. Chemical screening for suppressors of pmr1Δ-mediated CFW sensitivity. (A) Small
sterile ﬁlters were loaded with individual compounds and placed onto a lawn of pmr1Δ
cells spread on CFW-containing medium. Compounds that were able to alleviate the
CFW-sensitivity of pmr1Δ cells by restoring their growth were scored as positive hits.
CaCl2 was used as a positive control. (B) 30 active compounds were initially found but
only 4 were validated. The dose-dependent effect of one of these compounds is shown.
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bases of calcium-related diseases aswell as the targets of calcium action.
Such targets include Ca2+ transporters [102], Ca2+ binding proteins
such as calmodulin [47] and Ca2+ receptors or proteins involved in
maintaining intra-organelle Ca2+ levels [103]. Alterations in cellular
Ca2+ homeostasis have pleiotropic effects which make it difﬁcult to
suppress disease phenotypes. Ion contents usually vary from organelle
to organelle and in the case of Ca2+, such gradients become especially
important based on the fact that the calcium acts as a major signaling
molecule [36]. In addition, Ca2+-dependent chaperones are essential
to control the exclusive export of fully folded proteins from the endo-
plasmic reticulum [104]. Yeast might also serve as a model system to
study other humandisorders that link Ca2+ to protein-glycosylation de-
fects than HDD. Recently, a complementation study allowed the identi-
ﬁcation of the yeast Gdt1 protein as a functional homolog of the human
protein TMEM165 [105]. Mutations in TMEM165 are known to cause
a subtype of congenital disorders of glycosylation (CDG) [106] and
TMEM165 is now proposed to be a member of a unique family of
Golgi-localized Ca2+/H+ antiporters [105]. It is conceivable that Gdt1
mutants provide a putative yeast model system to search for modula-
tors of TMEM165-dependent CDG [107]. It is interesting to note that,
to date, about 50 different CDG types have been identiﬁed, most of
them affecting protein glycosylation (defects in N-glycosylation,
O-glycosylation, and both N- and O-glycosylation) [106,108–110]. Asmost of the affected genes have functional homologs in yeast,
more yeast models of CDG will thus be available, making them an at-
tractive tool to search for compounds that, e.g., could bypass protein-
glycosylation defects.
One of the challenges for the future is to screen for compounds that
suppress different pmr1mutant phenotypes, taking into consideration
the possibility to use pmr1 separation-of-function mutants affected in
either Ca2+ orMn2+ transport into theGolgi [111,112], aswell as differ-
ent ATP2C1mutant alleles [113–116]. Themutation spectrum of ATP2C1
mutant alleles includes nonsensemutations (premature stop codons) in
various exons that disrupt production of full-length, functional SPCA1
protein [113–121]. It is conceivable that HHD disease patients having
suchmutations beneﬁt from a treatmentwith compounds that e.g., pro-
mote the ribosomal readthrough of premature stop codons in ATP2C1
mRNA. Possibly, a yeast-based screening approachmight allow isolating
such molecules with a targeted mode of action, thereby avoiding com-
pounds having the drawback to confer a broad spectrum of action and
unwanted side effects. Hence, such approach holds promise for the de-
velopment of personalized therapeutics for HHD. This is a long way to
go but the combined efforts of interdisciplinary research should hope-
fully enlighten our understanding on mechanisms and treatment of
rare diseases, in particular calcium-related diseases such as HHD.Acknowledgements
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